Mycophenolate Mofetil versus Cyclosporine in Children with Frequent Relapse Nephrotic Syndrome
Journal of Pediatric Nephrology,
Vol. 6 No. 1 (2018),
4 May 2018
,
Page 1-6
https://doi.org/10.22037/jpn.v6i1.20904
Abstract
Introduction: Children with frequently relapsing nephrotic syndrome (FRNS) frequently develop adverse effects of prednisolone and attempts to induce long term remission in such patients have varying degree of success.
Materials & Methods: We conducted a randomized clinical trial in a tertiary care level hospital to compare the efficacy and safety of a 1 year treatment with mycophenolate mofetil (MMF) and Cyclosporine (CsA) in 60 pediatric patients with FR-SSNS during one year period. We assessed the frequency of relapse as the primary end point and evaluated clinical and laboratory profile after 3 and 6 months of treatment.
Results: Mean number of relapse was 1.50 ± 1.44 in MMF group and 0.72 ± 1.30 in CsA group at 6 months (p=0.045). Diarrhoea was statistically significant in MMF group. Hypertrichosis & hypertension were statistically significant in CsA group. There was no significant difference between groups with Hb levels, lipid profile, eGFR.
Conclusion: The result of the study showed MMF is inferior to CsA in preventing relapse in patient with FRNS but less nephrotoxic.
- Cyclosporine. Frequently relapsing. Mycophenolate mofetil. Nephrotic syndrome.
How to Cite
References
International Study of Kidney Disease in Children. Nephrotic Syndrome in Children; prediction of histopathology from clinical and laboratory characteristics at time of diagnosis, A report of the International Study of Kidney Disease in Children. Kidney International 1978; 13:159-165.
Dorresteijn EM, Joana E, Holthe KV, Levtchenko EN, Nauta J, Wim C, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatric Nephrology 2008; 23:2013-2020.
Latta K, Schnakenburg CV, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatric Nephrology 2001;16:271-282.
Bagga A, Srivastava RN. Nephrotic Syndrome’ In Srivastava RN and Bagga A (eds.), Pediatric Nephrology, 5th ed, Jaypee, New Delhi, 2011:195-234.
Jensen CJ, Shrivastava S, Taber DJ, Weimert NA, Shatat IF, Orak J, et al. A critical analysis of racial difference with mycophenolate mofetil (MMF) dosing, clinical outcomes and adverse effects in pediatric kidney transplant patients.Clinical Transplantion 2011; 25(4):534-540.
Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clinical Pharmacology and Theraputics2000; 68(5): 478-486.
Schwartz GJ and Work DF. Measurement and Estimation of GFR in Children and Adolescents. Clin J Am Soc Nephrol 2009;94: 1832–1843.
Yamaguchi I, Flyn, TJ. Pathophysiology of Hypertension. In:Avner ED, Harmon, WE, Niaudet P, Yoshikawa N. (Eds) Pediatric Nephrology 6th . USA:Springer;2009:1485-1507.
Gellermann J, Weber L, Pape L, Tönshoff B, Hoyer P, Querfeld U. Mycophenolate Mofetil versus Cyclosporin A in Children with Frequently Relapsing Nephrotic Syndrome. Journal of American Society of Nephrology 2013; 24: 1689-1697.
van Besouw NM, van der Mast BJ, Smak Gregoor PJ, Hesse CJ, IJzermans JN, van Gelder T, Weimar W. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplantpatients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999; 14:2710–2713.
Arbeiter K, Greenbaum L, Balzar E, Müller T, Hofmeister F, Bidmon B, Aufricht C. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol 2000;14:195–197.
- Abstract Viewed: 334 times
- PDF Downloaded: 264 times